{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:39:31Z","timestamp":1793093971559,"version":"4.5.0"},"reference-count":284,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.dld.2021.04.029","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T08:07:45Z","timestamp":1639642065000},"page":"170-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)"],"prefix":"10.1016","volume":"54","author":[{"given":"Giulio","family":"Marchesini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Burra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Miele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Alisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Vajro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Masarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Petta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Persico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Svegliati-Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Purrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando Carlo","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruccio","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Camm\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Colli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2021.04.029_bib0001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0002","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0003","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/joim.12719","article-title":"Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver","volume":"283","author":"Dongiovanni","year":"2018","journal-title":"J Intern Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0004","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0006","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0007","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.20689","article-title":"Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town","volume":"41","author":"Pendino","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0008","first-page":"77","article-title":"Association of non-alcoholic fatty liver disease and cardiometabolic risk factors with early atherosclerosis in an adult population in Southern Italy","volume":"53","author":"Caserta","year":"2017","journal-title":"Ann Ist Super Sanita"},{"key":"10.1016\/j.dld.2021.04.029_bib0009","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/liv.13743","article-title":"Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population","volume":"38","author":"Petta","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.04.029_bib0010","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2021.04.029_bib0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000087295","article-title":"Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy","volume":"49","author":"Colicchio","year":"2005","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0012","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00592-012-0406-1","article-title":"Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society","volume":"50","author":"Soresi","year":"2013","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.dld.2021.04.029_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/0003-4819-132-2-200001180-00004","article-title":"Prevalence of and risk factors for hepatic steatosis in Northern Italy","volume":"132","author":"Bellentani","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0014","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF03347199","article-title":"Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome","volume":"28","author":"Marchesini","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.dld.2021.04.029_bib0015","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2021.04.029_bib0016","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0017","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.dld.2021.04.029_bib0018","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0019","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2931985","article-title":"The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes","volume":"2016","author":"Forlani","year":"2016","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.dld.2021.04.029_bib0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1042\/CS20130036","article-title":"Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes","volume":"125","author":"Targher","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.dld.2021.04.029_bib0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diabres.2017.10.023","article-title":"Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patients","volume":"135","author":"Giorda","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dld.2021.04.029_bib0022","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.diabet.2016.04.002","article-title":"Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: causal association or epiphenomenon?","volume":"42","author":"Targher","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0023","doi-asserted-by":"crossref","first-page":"E526","DOI":"10.1503\/cmaj.092144","article-title":"Newly diagnosed diabetes mellitus as a risk factor for serious liver disease","volume":"182","author":"Porepa","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.dld.2021.04.029_bib0024","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jhep.2016.01.014","article-title":"Type 2 diabetes and risk of hospital admission or death for chronic liver diseases","volume":"64","author":"Wild","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0025","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ajg.2014.132","article-title":"Mortality from chronic liver diseases in diabetes","volume":"109","author":"Zoppini","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0026","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.diabet.2019.11.003","article-title":"Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD","volume":"46","author":"Sun","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0027","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0028","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.numecd.2020.02.016","article-title":"Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy","volume":"30","author":"Petta","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.dld.2021.04.029_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2020.02.016","article-title":"Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy","author":"Petta","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.dld.2021.04.029_bib0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0031","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2016.03.005","article-title":"Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0032","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.numecd.2016.06.011","article-title":"The association of lean and fat mass with all-cause mortality in older adults: the cardiovascular health study","volume":"26","author":"Spahillari","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.dld.2021.04.029_bib0033","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0034","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/eurheartj\/ehr453","article-title":"Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?","volume":"33","author":"Bhatia","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dld.2021.04.029_bib0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0036","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0037","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0038","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0039","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0040","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1210\/jc.2013-1519","article-title":"Resolution of fatty liver and risk of incident diabetes","volume":"98","author":"Sung","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0041","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2337\/dc15-0140","article-title":"Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes","volume":"38","author":"Yamazaki","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2021.04.029_bib0042","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.dld.2021.04.029_bib0043","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0044","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world","volume":"20","author":"Sayiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dld.2021.04.029_bib0045","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Mortality and causes of death collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.04.029_bib0046","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0047","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0048","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0049","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0050","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2017.10.006","article-title":"Should we undertake surveillance for HCC in patients with NAFLD?","volume":"68","author":"Younes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0051","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0052","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team","volume":"60","author":"Dyson","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0053","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26986","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0054","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0055","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0056","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0038-1677517","article-title":"NASH in lean individuals","volume":"39","author":"Younes","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.dld.2021.04.029_bib0057","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jgh.15156","article-title":"Global epidemiology of lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"35","author":"Lu","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0058","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ajg.2016.318","article-title":"Clinical and metabolic characterization of lean caucasian subjects with non-alcoholic fatty liver","volume":"112","author":"Feldman","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0059","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.metabol.2012.08.005","article-title":"In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not","volume":"62","author":"Younossi","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.dld.2021.04.029_bib0060","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jhep.2010.09.037","article-title":"Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity","volume":"54","author":"Fracanzani","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0061","article-title":"Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease","volume":"146","author":"Dela Cruz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0062","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study","volume":"2","author":"Hagstrom","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2021.04.029_bib0063","series-title":"Manuale metodologco per la Produzione di Linee Guida di Pratica Clinica. Roma: ISS - Istituto Superiore di Sanit\u00e0","year":"2020"},{"key":"10.1016\/j.dld.2021.04.029_bib0064","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.dld.2021.04.029_bib0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12961-018-0320-2","article-title":"The GRADE Evidence to Decision (EtD) framework for health system and public health decisions","volume":"16","author":"Moberg","year":"2018","journal-title":"Health Res Policy Syst"},{"key":"10.1016\/j.dld.2021.04.029_bib0066","series-title":"GRADEpro guideline development tool","year":"2020"},{"key":"10.1016\/j.dld.2021.04.029_bib0067","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0068","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2021.04.029_bib0069","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2021.04.029_bib0070","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0071","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0072","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cgh.2017.08.024","article-title":"Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: a systematic review and meta-analysis","volume":"16","author":"Verhaegh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2021.04.029_bib0073","doi-asserted-by":"crossref","first-page":"e001174","DOI":"10.1136\/bmjdrc-2020-001174","article-title":"Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels","volume":"8","author":"Zheng","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.dld.2021.04.029_bib0074","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0076","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0077","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH - current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0078","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0079","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0080","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0081","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.04.029_bib0082","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0083","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study","volume":"46","author":"Sun","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.dld.2021.04.029_bib0084","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0085","doi-asserted-by":"crossref","first-page":"916","DOI":"10.14309\/ajg.0000000000000153","article-title":"Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease","volume":"d114","author":"Petta","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0086","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/liv.13549","article-title":"Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease","volume":"38","author":"Joo","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.04.029_bib0087","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/liv.13739","article-title":"Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease","volume":"38","author":"Bertot","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.04.029_bib0088","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc19-1071","article-title":"Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes","volume":"43","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2021.04.029_bib0089","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0090","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/apt.15529","article-title":"Direct comparison of the specialised blood fibrosis tests fibrometer(V2G) and enhanced liver fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres","volume":"50","author":"Guillaume","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.029_bib0091","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1136\/gutjnl-2018-317334","article-title":"Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease","volume":"68","author":"Wong","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.04.029_bib0092","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0093","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0094","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/hep.27844","article-title":"The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease","volume":"62","author":"Petta","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0095","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.28843","article-title":"Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values","volume":"65","author":"Petta","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0096","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/apt.14529","article-title":"Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement","volume":"47","author":"Karlas","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.029_bib0097","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0098","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/hep.28394","article-title":"Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy","volume":"63","author":"Cassinotto","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0099","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/apt.14219","article-title":"Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD","volume":"46","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.029_bib0100","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/liv.12584","article-title":"The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"35","author":"Petta","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.04.029_bib0101","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jhep.2017.01.003","article-title":"A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis","volume":"66","author":"Boursier","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0102","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0103","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0104","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"145","author":"Angulo","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0105","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.cgh.2018.11.030","article-title":"Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease","volume":"17","author":"Hagstrom","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128774","article-title":"Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis","volume":"10","author":"Sebastiani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2021.04.029_bib0107","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/00365521.2019.1583366","article-title":"Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD)","volume":"54","author":"Onnerhag","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0108","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jhep.2016.04.023","article-title":"Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease","volume":"65","author":"Boursier","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0109","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/apt.14990","article-title":"Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease","volume":"48","author":"Munteanu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.029_bib0110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ajg.2011.327","article-title":"Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma","volume":"107","author":"Kawamura","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0111","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/liv.14301","article-title":"Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease","volume":"40","author":"Shili-Masmoudi","year":"2019","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.dld.2021.04.029_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.06.045","article-title":"Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease","volume":"19","author":"Petta","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0113","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstrom","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0114","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0115","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jhep.2013.12.009","article-title":"A population-based study on the prevalence of NASH using scores validated against liver histology","volume":"60","author":"Hyysalo","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0116","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0117","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0118","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.2174\/1381612825666190119113836","article-title":"Genetics of nonalcoholic fatty liver disease: a 2018 update","volume":"24","author":"Valenti","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.dld.2021.04.029_bib0119","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cgh.2019.08.011","article-title":"Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease","volume":"18","author":"Grimaudo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0121","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jhep.2014.12.028","article-title":"Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance","volume":"62","author":"Anstee","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0122","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1038\/s41598-019-39998-2","article-title":"Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease","volume":"9","author":"Pelusi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.dld.2021.04.029_bib0123","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/tpj.2017.45","article-title":"The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro","volume":"18","author":"Pillai","year":"2018","journal-title":"Pharmacogenom J"},{"key":"10.1016\/j.dld.2021.04.029_bib0124","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/jgh.14894","article-title":"Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease","volume":"35","author":"Liu","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0125","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0126","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2013.09.015","article-title":"Body mass index in childhood and adult risk of primary liver cancer","volume":"60","author":"Berentzen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0127","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006998","article-title":"Body mass index in school-aged children and the risk of routinely diagnosed non-alcoholic fatty liver disease in adulthood: a prospective study based on the Copenhagen school health records register","volume":"5","author":"Zimmermann","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.dld.2021.04.029_bib0128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2016.03.019","article-title":"Overweight in late adolescence predicts development of severe liver disease later in life: a 39years follow-up study","volume":"65","author":"Hagstrom","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0129","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.20543","article-title":"Chronological development of elevated aminotransferases in a nonalcoholic population","volume":"41","author":"Suzuki","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2014.08.041","article-title":"Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy","volume":"62","author":"Wong","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0131","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/hr.2010.45","article-title":"Fatty liver incidence and predictive variables","volume":"33","author":"Tsuneto","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.dld.2021.04.029_bib0132","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2011.12.011","article-title":"Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up","volume":"56","author":"Zelber-Sagi","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0133","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/oby.2010.254","article-title":"Cognitive-behavioral treatment of non-alcoholic fatty liver disease: a propensity score-adjusted observational study","volume":"19","author":"Moscatiello","year":"2011","journal-title":"Obesity"},{"key":"10.1016\/j.dld.2021.04.029_bib0134","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0135","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.22009","article-title":"Fatty Liver Italian N. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach","volume":"47","author":"Bellentani","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0136","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice","volume":"63","author":"Marchesini","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0137","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jhep.2018.07.013","article-title":"An internet-based approach for lifestyle changes in patients with NAFLD: two-year effects on weight loss and surrogate markers","volume":"69","author":"Mazzotti","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0138","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-Gomez","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0139","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/apt.13860","article-title":"Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis","volume":"45","author":"Vilar-Gomez","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.029_bib0140","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0141","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.04.029_bib0142","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0143","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cld.2009.07.006","article-title":"Lifestyle modification as the primary treatment of NASH","volume":"13","author":"Neuschwander-Tetri","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dld.2021.04.029_bib0144","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.gastro.2015.06.015","article-title":"Weight loss for a healthy liver","volume":"149","author":"Marchesini","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0145","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2174\/1381612826666200204095401","article-title":"Lifestyle changes for the treatment of nonalcoholic fatty liver disease \u2013 a 2015-19 update","volume":"26","author":"Petroni","year":"2020","journal-title":"Curr Pharma Des"},{"key":"10.1016\/j.dld.2021.04.029_bib0146","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023597","article-title":"Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study","volume":"9","author":"Vilar-Gomez","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.dld.2021.04.029_bib0147","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0148","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clnu.2013.08.014","article-title":"Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease","volume":"33","author":"Kontogianni","year":"2014","journal-title":"Clin Nutr"},{"key":"10.1016\/j.dld.2021.04.029_bib0149","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0150","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0151","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2009.05.033","article-title":"Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome","volume":"51","author":"Abid","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0152","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/hep.22525","article-title":"Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study","volume":"48","author":"Zelber-Sagi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0153","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2015.07.010","article-title":"Relationship of sitting time and physical activity with non-alcoholic fatty liver disease","volume":"63","author":"Ryu","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0154","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.22940","article-title":"Independent effects of physical activity in patients with nonalcoholic fatty liver disease","volume":"50","author":"St George","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0155","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0156","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1586\/17474124.2015.1075392","article-title":"The benefits of exercise for patients with non-alcoholic fatty liver disease","volume":"9","author":"Keating","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0157","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/gutjnl-2013-305718","article-title":"Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals","volume":"63","author":"Sookoian","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.04.029_bib0158","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jhep.2012.03.024","article-title":"Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"57","author":"Dunn","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0159","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.30170","article-title":"Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study","volume":"69","author":"Chang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0160","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/hep.30867","article-title":"Low levels of alcohol consumption, obesity, and development of fatty liver with and without evidence of advanced fibrosis","volume":"71","author":"Chang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0161","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.cgh.2018.01.026","article-title":"Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis","volume":"16","author":"Ajmera","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0162","doi-asserted-by":"crossref","first-page":"876","DOI":"10.14309\/ajg.0000000000000607","article-title":"Light-to-moderate alcohol consumption is associated with increased risk of type 2 diabetes in individuals with nonalcoholic fatty liver disease: A nne-year cohort study","volume":"115","author":"Xu","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0163","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1053\/j.gastro.2017.08.012","article-title":"Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease","volume":"153","author":"VanWagner","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0164","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.30864","article-title":"Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts","volume":"71","author":"Aberg","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0165","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/hep.30226","article-title":"Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study","volume":"70","author":"Hajifathalian","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0166","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0167","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2337\/diacare.25.12.2165","article-title":"The Diabetes Prevention Program (DPP): description of lifestyle intervention","volume":"25","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2021.04.029_bib0168","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"RR","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0169","doi-asserted-by":"crossref","first-page":"e60495","DOI":"10.1371\/journal.pone.0060495","article-title":"Long-term effect of bariatric surgery on liver enzymes in the Swedish obese subjects (SOS) study","volume":"8","author":"Burza","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2021.04.029_bib0170","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1001\/jama.2014.5988","article-title":"Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications","volume":"311","author":"Sjostrom","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2021.04.029_bib0171","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0172","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0173","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","article-title":"Bariatric surgery and long-term cardiovascular events","volume":"307","author":"Sjostrom","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2021.04.029_bib0174","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1200111","article-title":"Bariatric surgery versus conventional medical therapy for type 2 diabetes","volume":"366","author":"Mingrone","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0175","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00125-015-3591-y","article-title":"Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study","volume":"58","author":"Sjoholm","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.dld.2021.04.029_bib0176","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/hep.28958","article-title":"Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis","volume":"65","author":"Klebanoff","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0177","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0178","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0179","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0180","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0181","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0182","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0183","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.24558","article-title":"Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial","volume":"54","author":"Torres","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0184","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jceh.2012.10.010","article-title":"A randomized controlled trial comparing efficacy of pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis","volume":"2","author":"Sharma","year":"2012","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0185","doi-asserted-by":"crossref","first-page":"e9270","DOI":"10.5812\/hepatmon.9270","article-title":"The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic fatty liver disease: a randomized double blinded clinical trial","volume":"13","author":"Razavizade","year":"2013","journal-title":"Hepat Mon"},{"key":"10.1016\/j.dld.2021.04.029_bib0186","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0187","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.28960","article-title":"Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: new evidence, new challenges","volume":"65","author":"Musso","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0188","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/liv.14385","article-title":"Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes","volume":"40","author":"Yen","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.04.029_bib0189","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.04.029_bib0190","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0191","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2021.04.029_bib0192","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s00125-015-3660-2","article-title":"The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis","volume":"58","author":"Billington","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.dld.2021.04.029_bib0193","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013927","article-title":"Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Liao","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.dld.2021.04.029_bib0194","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/hep.25887","article-title":"Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis","volume":"56","author":"Mahady","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0195","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/apt.12352","article-title":"Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis","volume":"38","author":"Hoofnagle","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.029_bib0196","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.nut.2014.11.018","article-title":"Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"31","author":"Sato","year":"2015","journal-title":"Nutrition"},{"key":"10.1016\/j.dld.2021.04.029_bib0197","first-page":"3924","article-title":"Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis","volume":"8","author":"Xu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0198","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2021.04.029_bib0199","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0200","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jama.297.8.842","article-title":"Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis","volume":"297","author":"Bjelakovic","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2021.04.029_bib0201","doi-asserted-by":"crossref","first-page":"c5702","DOI":"10.1136\/bmj.c5702","article-title":"Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials","volume":"341","author":"Schurks","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2021.04.029_bib0202","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2021.04.029_bib0203","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.cgh.2006.09.025","article-title":"Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis","volume":"4","author":"Dufour","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0204","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0205","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0206","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis","volume":"54","author":"Ratziu","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0207","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.04.029_bib0208","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.04.029_bib0209","series-title":"Intercept pharmaceuticals: update on intercept's NDA submission to the FDA","year":"2020"},{"key":"10.1016\/j.dld.2021.04.029_bib0210","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0211","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0212","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2021.04.029_bib0213","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MEG.0b013e32832e2baf","article-title":"Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease","volume":"22","author":"Omer","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0214","first-page":"OC19","article-title":"Comparative effect of insulin sensitizers and statin on metabolic profile and ultrasonographical score in non alcoholic fatty liver disease","volume":"10","author":"Rana","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.dld.2021.04.029_bib0215","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/jc.2012-1267","article-title":"Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"97","author":"Zhang","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0216","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0217","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2014-3794","article-title":"Effect of vildagliptin on hepatic steatosis","volume":"100","author":"Macauley","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0218","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/MEG.0000000000000780","article-title":"Short article: a randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease","volume":"29","author":"Deng","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0219","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0220","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2021.04.029_bib0221","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.029_bib0222","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/dmrr.2561","article-title":"Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes","volume":"30","author":"Shao","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.dld.2021.04.029_bib0223","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0224","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.13053","article-title":"Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial","volume":"20","author":"Frossing","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0225","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1753-0407.12555","article-title":"Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease","volume":"9","author":"Feng","year":"2017","journal-title":"J Diabetes"},{"key":"10.1016\/j.dld.2021.04.029_bib0226","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dld.2021.04.029_bib0227","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0228","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dld.2021.04.029_bib0229","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME(R) trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.dld.2021.04.029_bib0230","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2021.04.029_bib0231","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2021.04.029_bib0232","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.dld.2021.04.029_bib0233","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0234","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0235","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","article-title":"Effect of canagliflozin on liver function tests in patients with type 2 diabetes","volume":"42","author":"Leiter","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0236","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.dld.2021.04.029_bib0237","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0238","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dld.2021.04.029_bib0239","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-019-0903-4","article-title":"Class effects of SGLT2 inhibitors on cardiorenal outcomes","volume":"18","author":"Kluger","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dld.2021.04.029_bib0240","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study","volume":"71","author":"Haldar","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0241","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cgh.2013.09.023","article-title":"Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0242","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/TP.0000000000002433","article-title":"International Liver Transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation","volume":"103","author":"Tsochatzis","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2021.04.029_bib0243","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"Stine","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.029_bib0244","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0245","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1161\/CIRCULATIONAHA.114.009278","article-title":"Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study","volume":"130","author":"An","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2021.04.029_bib0246","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/lt.25012","article-title":"Coronary artery disease in decompensated patients undergoing liver transplantation evaluation","volume":"24","author":"Patel","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2021.04.029_bib0247","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/TP.0000000000001710","article-title":"Incidence of and risk assessment for adverse cardiovascular outcomes after liver transplantation: a systematic review","volume":"101","author":"Konerman","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2021.04.029_bib0248","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/lt.24987","article-title":"Cardiac function, a key component in evaluation for liver transplant","volume":"24","author":"Yotti","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2021.04.029_bib0249","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00007890-199503270-00010","article-title":"The prevalence of coronary artery disease in liver transplant candidates over age 50","volume":"59","author":"Carey","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2021.04.029_bib0250","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/lt.500020604","article-title":"Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation","volume":"2","author":"Plotkin","year":"1996","journal-title":"Liver Transpl Surg"},{"key":"10.1016\/j.dld.2021.04.029_bib0251","first-page":"1633","article-title":"Prognostic implications of combined prone and supine acquisitions in patients with equivocal or abnormal supine myocardial perfusion SPECT","volume":"44","author":"Hayes","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.dld.2021.04.029_bib0252","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.transproceed.2008.05.069","article-title":"Microvascular autonomic dysfunction may justify false-positive stress myocardial perfusion imaging in patients with liver cirrhosis undergoing liver transplantation","volume":"40","author":"Senzolo","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2021.04.029_bib0253","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/TP.0000000000002485","article-title":"Management of recurrent and de novo NAFLD\/NASH after liver transplantation","volume":"103","author":"Germani","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2021.04.029_bib0254","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1161\/CIR.0000000000000105","article-title":"2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"130","author":"Fleisher","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2021.04.029_bib0255","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0256","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/jhep.2002.30318","article-title":"Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States","volume":"35","author":"Nair","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0257","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/TP.0000000000002483","article-title":"Recommendations for management and treatment of nonalcoholic steatohepatitis","volume":"103","author":"Ratziu","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2021.04.029_bib0258","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12881","article-title":"The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US","volume":"40","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.029_bib0259","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cgh.2011.07.007","article-title":"Increased perioperative mortality following bariatric surgery among patients with cirrhosis","volume":"9","author":"Mosko","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0260","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.soard.2013.02.013","article-title":"Laparoscopic sleeve gastrectomy is safe and efficacious for pretransplant candidates","volume":"9","author":"Lin","year":"2013","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.dld.2021.04.029_bib0261","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.soard.2007.12.009","article-title":"Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation","volume":"4","author":"Takata","year":"2008","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.dld.2021.04.029_bib0262","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1007\/s11695-017-2854-8","article-title":"The role of bariatric surgery in abdominal organ transplantation-the next big challenge?","volume":"27","author":"Dziodzio","year":"2017","journal-title":"Obes Surg"},{"key":"10.1016\/j.dld.2021.04.029_bib0263","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1600-6143.2012.04318.x","article-title":"Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease","volume":"13","author":"Heimbach","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.dld.2021.04.029_bib0264","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0265","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.029_bib0266","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0267","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/j.gastro.2018.04.014","article-title":"Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease","volume":"155","author":"Ajmera","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.029_bib0268","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/jlts.2002.36740","article-title":"One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation","volume":"8","author":"Ryan","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2021.04.029_bib0269","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.3748\/wjg.v20.i23.7392","article-title":"Radiologic evaluation of nonalcoholic fatty liver disease","volume":"20","author":"Lee","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0270","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1007\/s00330-019-06072-4","article-title":"Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"29","author":"Gu","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.dld.2021.04.029_bib0271","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2017.11.028","article-title":"Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions","volume":"68","author":"Loomba","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0272","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12876-019-0961-9","article-title":"Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"19","author":"Pu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0273","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis","volume":"6","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0274","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.29639","article-title":"Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis","volume":"67","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0275","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/jgh.14150","article-title":"Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?","volume":"33","author":"Chan","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0276","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0277","series-title":"Principles and practice of screening for disease","author":"Wilson","year":"1968"},{"key":"10.1016\/j.dld.2021.04.029_bib0278","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2013.05.044","article-title":"From NAFLD in clinical practice to answers from guidelines","volume":"59","author":"Nascimbeni","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0279","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in non-alcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.029_bib0280","doi-asserted-by":"crossref","first-page":"i3139","DOI":"10.1136\/bmj.i3139","article-title":"The spectrum effect in tests for risk prediction, screening, and diagnosis","volume":"353","author":"Usher-Smith","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2021.04.029_bib0281","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S2468-1253(16)30205-9","article-title":"Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review","volume":"2","author":"Harris","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.029_bib0282","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.3399\/bjgp18X699377","article-title":"GPs' experiences and perceptions of early detection of liver disease: a qualitative study in primary care","volume":"68","author":"Standing","year":"2018","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.dld.2021.04.029_bib0283","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"Srivastava","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.029_bib0284","doi-asserted-by":"crossref","first-page":"m4747","DOI":"10.1136\/bmj.m4747","article-title":"Management of non-alcoholic fatty liver disease","volume":"372","author":"Petroni","year":"2021","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1016\/j.dld.2023.01.152","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000}}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821002140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821002140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T20:25:51Z","timestamp":1657916751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821002140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":284,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1590865821002140"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.04.029","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}